Literature DB >> 8249042

Morphine pharmacokinetics and effects on salivation and continuous reaction times in healthy volunteers.

D Westerling1, L Frigren, P Höglund.   

Abstract

Ten healthy volunteers were given an i.v. infusion of 10 mg morphine HCl, an oral solution of 20 mg morphine HCl, or a new controlled release tablet of 30 mg morphine sulphate on three separate occasions in a complete crossover design. Venous blood samples were collected serially for 14-24 h and analyzed for morphine using high-performance liquid chromatography (HPLC). Continuous reaction times (CRTs) and salivation were measured repeatedly in all subjects. Oxygen saturation remained normal throughout the procedure. Five subjects experienced nausea on at least one occasion. Pharmacokinetic parameters, calculated using a two-compartment model, were in accordance with previous results for i.v. and oral administration of morphine solutions. The absolute bioavailability of morphine in the oral solution was 21.6% (15.4-27.7%; 95% CI) and in the controlled release tablet, 17.1% (12.6-21.6%; CI). Secondary peaks in the plasma concentration curves strongly indicated an enterohepatic circulation (EHC) of morphine. Alternative pharmacokinetic calculations, including EHC, were performed and used in a pharmacokinetic-pharmacodynamic model, in which the studied effects were well correlated to the concentrations of morphine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8249042     DOI: 10.1097/00007691-199310000-00003

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  9 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

Review 2.  Oral morphine for cancer pain.

Authors:  Philip J Wiffen; Bee Wee; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2016-04-22

3.  A double-blind study of the sedative effects of the thalidomide enantiomers in humans.

Authors:  P Höglund; T Eriksson; S Björkman
Journal:  J Pharmacokinet Biopharm       Date:  1998-08

4.  Transdermal administration of morphine to healthy subjects.

Authors:  D Westerling; P Höglund; S Lundin; P Svedman
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

5.  Effect modelling for drugs undergoing enterohepatic circulation.

Authors:  P Höglund; M Ohlin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Oct-Dec       Impact factor: 2.441

Review 6.  Opioid analgesics: comparative features and prescribing guidelines.

Authors:  N I Cherny
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

7.  Pharmacogenetic pathway analysis of irinotecan.

Authors:  G L Rosner; J C Panetta; F Innocenti; M J Ratain
Journal:  Clin Pharmacol Ther       Date:  2008-04-16       Impact factor: 6.875

8.  Pharmacokinetics, tissue distribution and mass balance of radiolabeled dihydroartemisinin in male rats.

Authors:  Lisa H Xie; Qigui Li; Jing Zhang; Peter J Weina
Journal:  Malar J       Date:  2009-05-26       Impact factor: 2.979

9.  Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients.

Authors:  Hanne H Villesen; Anne-Marie Banning; Rasmus H Petersen; Sebatian Weinelt; Jesper B Poulsen; Steen H Hansen; Lona L Christrup
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.